Objective: The aim of this study was to evaluate the protein quality of products used in the nutritional treatment of phenylketonuria (PKU) and maple syrup urine disease (MSUD). Material and Methods: Protein digestibility corrected amino acid score (PDCAAS) method was used to evaluate protein quality. Thirty two products including 14 PKU Specialty Products, 5 PKU-glycomacroeptide (PKU-GMP) products and 13 MSUD products were analyzed. Results: PDCAAS scores of PKU products were between 94-100%; PDCAAS scores of PKU-GMP products were between 35- 99%. In general, the limiting amino acids were the sulfur amino acid group with 11 products. The PDCAAS score of MSUD products was between 24-49% and the limiting amino acids of these products were commonly sulfurous amino acid group. Conclusion: Present study revealed that the protein quality and PDCAAS value of PKU specialty products (except PKU-GMP) were generally high. PDCAAS value of PKU-GMP specialty products differed among themselves. The differences between PDCAAS value of PKU-GMP specialty products may attributed to the variability of amino acids supplemented in the products. In MSUD products, protein quality and PDCAAS value were generally lower than PKU specialty products (except PKU-GMP), which related to the limitation of valine, isoleucine, and leucine. Studies on therapeutic foods developed against congenital amino acid disorders are limited; further studies are needed.
Keywords: Phenylketonuria; maple syrup urine disease; congenital metabolic disorders; protein digestibility corrected amino acid score; protein quality
Amaç: Bu çalışmanın amacı, fenilketonüri [Phenylketonuria (PKU)] ve akçaağaç şurubu idrar hastalığı [Maple Syrup Urine Disease (MSUD)] beslenme tedavisinde kullanılan ürünlerin protein kalitesinin değerlendirilmesidir. Gereç ve Yöntemler: Protein kalitesinin değerlendirilmesinde protein sindirilebilirliği düzeltilmiş amino asit skoru [Protein Digestibility Corrected Amino Acid Score (PDCAAS)] yöntemi kullanılmıştır. On dört PKU Özel Ürünü, 5 PKU-glikomakroeptit (PKU-GMP) ürünü, 13 MSUD ürünü olmak üzere 32 ürün incelenmiştir. Bulgular: PKU ürünlerinin PDCAAS skoru %94-100 arasında; PKU-GMP ürünlerinin PDCAAS skoru %35-99 arasında bulunmuştur. Genel olarak sınırlayıcı amino asitleri 11 ürün ile sülfürlü amino asit grubu olmuştur. MSUD ürünlerinin PDCAAS skoru %24-49 arasında bulunmuştur ve bu ürünlerin sınırlayıcı amino asitleri yaygın olarak sülfürlü amino asit grubu olmuştur. Sonuç: Mevcut çalışma, PKU özel ürünlerinin (PKU-GMP hariç) protein kalitesinin ve PDCAAS değerinin genel olarak yüksek olduğunu ortaya koymuştur. PKU-GMP özel ürünlerinin PDCAAS değeri kendi aralarında farklılık göstermiştir. PKU-GMP özel ürünlerinin PDCAAS değerleri arasındaki farklılıklar, ürünlere eklenen amino asitlerin değişkenliğine bağlanabilir. MSUD ürünlerinde protein kalitesi ve PDCAAS değeri, valin, izolösin ve lösin sınırlamasıyla ilişkili olarak PKU özel ürünlerinden (PKU-GMP hariç) genellikle daha düşüktür. Konjenital amino asit bozukluklarına karşı geliştirilen terapötik gıdalar üzerine çalışmalar sınırlıdır; daha fazla çalışmaya ihtiyaç vardır.
Anahtar Kelimeler: Fenilketonüri; akçaağaç şurubu idrar hastalığı; doğuştan metabolizma bozuklukları; protein sindirilebilirliği düzeltilmiş amino asit skoru; protein kalitesi
- Ezgu F. Inborn errors of metabolism. Adv Clin Chem. 2016;73:195-250. [PubMed]
- Ziegler SG, Kim J, Ehmsen JT, Vernon HJ. Inborn errors of amino acid metabolism - from underlying pathophysiology to therapeutic advances. Dis Model Mech. 2023;16(11):dmm050233. [Crossref] [PubMed] [PMC]
- MaCdonald A, van Rijn M, Feillet F, Lund AM, Bernstein L, Bosch AM, et al. Adherence issues in inherited metabolic disorders treated by low natural protein diets. Ann Nutr Metab. 2012;61(4):289-95. [Crossref] [PubMed]
- Elhawary NA, AlJahdali IA, Abumansour IS, Elhawary EN, Gaboon N, Dandini M, et al. Genetic etiology and clinical challenges of phenylketonuria. Hum Genomics. 2022;16(1):22. [Crossref] [PubMed] [PMC]
- Fermo KT, da Silva Lemos I, Farias HR, Rosso MP, Effting PS, Leipnitz G, et al. Branched-chain amino acids (BCAA) administration increases autophagy and the autophagic pathway in brain tissue of rats submitted to a Maple Syrup Urine Disease (MSUD) protocol. Metab Brain Dis. 2023;38(1):287-93. [Crossref] [PubMed]
- Skvorak K, Liu J, Kruse N, Mehmood R, Das S, Jenne S, et al. Oral enzyme therapy for maple syrup urine disease (MSUD) suppresses plasma leucine levels in intermediate MSUD mice and healthy nonhuman primates. J Inherit Metab Dis. 2023;46(6):1089-103. [Crossref] [PubMed]
- Handoom B, Megdad E, Al-Qasabi D, Al Mesned M, Hawary R, Al-Nufiee S, et al. The effects of low protein products availability on growth parameters and metabolic control in selected amino acid metabolism disorders patients. Int J Pediatr Adolesc Med. 2018;5(2):60-8. [Crossref] [PubMed] [PMC]
- Boye J, Wijesinha-Bettoni R, Burlingame B. Protein quality evaluation twenty years after the introduction of the protein digestibility corrected amino acid score method. Br J Nutr. 2012;108 Suppl 2:S183-211. [Crossref] [PubMed]
- Liu X, Chen H, Zhong Y, Lee TY, Han W, Yu D, et al. Diet therapy in patients with rare diseases: a scoping review. J Hum Nutr Diet. 2023;36(3):742-53. [Crossref] [PubMed]
- Lee WT, Weisell R, Albert J, Tomé D, Kurpad AV, Uauy R. Research approaches and methods for evaluating the protein quality of human foods proposed by an FAO expert working group in 2014. J Nutr. 2016;146(5):929-32. [Crossref] [PubMed]
- Leser S. The 2013 FAO report on dietary protein quality evaluation in human nutrition: Recommendations and implications. Nutrition Bulletin. 2013;38(4):421-8. [Crossref]
- WHO. Protein and amino acid requirements in human nutrition. World Health Organization technical report series. 2007. [Link]
- Marinangeli CPF, House JD. Potential impact of the digestible indispensable amino acid score as a measure of protein quality on dietary regulations and health. Nutr Rev. 2017;75(8):658-67. Erratum in: Nutr Rev. 2017;75(8):671. [Crossref] [PubMed] [PMC]
- FAO. Protein quality evaluation. 1991;51:1-66. [Link]
- Sarwar G, Botting HG, Peace RW. Amino acid rating method for evaluating protein adequacy of infant formulas. J Assoc Off Anal Chem. 1989;72(4):622-6. [PubMed]
- Pellegrino L, Masotti F, Cattaneo S, Hogenboom J, De Noni I. Nutritional quality of milk proteins. Advanced Dairy Chemistry: Volume 1A: Proteins: Basic Aspects. 4th ed. Berlin: Springer; 2013. p.515-38. [Crossref] [PubMed]
- Nguyen TT, Bhandari B, Cichero J, Prakash S. In vitro digestion of infant formulations with hydrolysed and non-hydrolysed proteins from dairy and soybean. Food Funct. 2016;7(12):4908-19. [Crossref] [PubMed]
- Boza JJ, Martínez-Augustin O, Baró L, Suarez MD, Gil A. Protein v. enzymic protein hydrolysates. Nitrogen utilization in starved rats. Br J Nutr. 1995;73(1):65-71. [PubMed]
- Baró L, Guadix EM, Martinez-Augustin O, Boza JJ, Gil A. Serum amino acid concentrations in growing rats fed intact protein versus enzymatic protein hydrolysate-based diets. Biol Neonate. 1995;68(1):55-61. [Crossref] [PubMed]
- Traves D. Understanding infant formula. Paediatrics and Child Health. 2019;29(9):384-8. [Link]
- van Calcar SC, Ney DM. Food products made with glycomacropeptide, a low-phenylalanine whey protein, provide a new alternative to amino acid-based medical foods for nutrition management of phenylketonuria. J Acad Nutr Diet. 2012;112(8):1201-10. [Crossref] [PubMed] [PMC]
- Daly A, Pinto A, Evans S, MacDonald A. Glycomacropeptide in PKU-does it live up to its potential? Nutrients. 2022;14(4):807. [Crossref] [PubMed] [PMC]
- Shivakumar N, Jackson AA, Courtney-Martin G, Elango R, Ghosh S, Hodgkinson S, et al. Protein quality assessment of follow-up formula for young children and ready-to-use therapeutic foods: recommendations by the FAO expert working group in 2017. J Nutr. 2020;150(2):195-201. [Crossref] [PubMed]
- FAO [Internet]. Protein Quality Assessment in Follow-up Formula for Young Children. © FAO 2025 [Cited: February 4, 2025]. Available from: [Link]
- Camp KM, Lloyd-Puryear MA, Huntington KL. Nutritional treatment for inborn errors of metabolism: indications, regulations, and availability of medical foods and dietary supplements using phenylketonuria as an example. Mol Genet Metab. 2012;107(1-2):3-9. [PubMed] [PMC]
- Keskin FN, Şahin TÖ, Capasso R, Ağagündüz D. Protein substitutions as new-generation pharmanutrition approach to managing phenylketonuria. Clin Exp Pediatr. 2023;66(8):320-31. [Crossref] [PubMed] [PMC]
- Roux LL, Chacon R, Dupont D, Jeantet R, Deglaire A, Nau F. In vitro static digestion reveals how plant proteins modulate model infant formula digestibility. Food Res Int. 2020;130:108917. [Crossref] [PubMed]
.: Process List